首页> 外文会议>World Congress on Heart Disese-International Academy of Cardiology Annual Scientific Session 2010 >Long-Term follow up of patients treated with paclitaxel-eluting stent with bioestable polymer versus bioresorbable polymer.
【24h】

Long-Term follow up of patients treated with paclitaxel-eluting stent with bioestable polymer versus bioresorbable polymer.

机译:长期跟进紫杉醇洗脱支架治疗的患者,具有生物可归属聚合物与生物可吸收聚合物。

获取原文

摘要

Objective: To compare the long term results of biodegradable polymer coated paclitaxel-eluting stents (Luc Chopin, Balton Ltd.) with biostable polymer coated paclitaxel-eluting stents (Taxus, Boston Scientific Corporation) in novo percutaneous coronary interventions (PCI). Materials and Methods: We studied 82 patients who consecutively underwent a PCI with paclitaxel-eluting stents between October 2007 and December 2008 with an average follow-up of 16 months. Results: Restenosis was found in 4 patients in the Taxus group and in 3 patients in the Luc Chopin group (8% versus 9.4%, respectively, NS). Progression of disease was observed in 4 patients of the first group and 1 of the second (8% versus 3.1%, respectively, NS). There were no incidents in 41 patients of the Taxus group and 26 patients of the Luc Chopin group (82% versus 81.25%, respectively; NS). Conclusions: Based on our clinical analyses, the Luc Chopin stent provided a combined profile of safety and efficacy non-inferior to the Taxus stent.
机译:目的:比较可生物降解聚合物涂层紫杉醇洗脱支架(Luc Chopin,Balton Ltd.)的长期结果,在Novo经皮冠状动脉干预(PCI)中具有生物聚合物涂层紫杉醇洗脱支架(Raxus,波士顿科学公司)。材料和方法:我们研究了82名患者,在2007年10月和2008年12月之间与紫杉醇洗脱支架进行了连续接受PCI的患者,平均随访16个月。结果:在4名患者中发现Reterenisis在Raxus组和3例患者中发现了Luc Chopin组(分别为9.4%,分别为9.4%)。在第一个第1组患者中观察到疾病的进展,其中1例(分别为8%,分别为3.1%,NS)。 41名患者的41名患者中没有事故,以及Luc Chopin组的26名患者(分别为81.25%,分别为81.25%)。结论:基于我们的临床分析,Luc Chopin支架提供了一种综合的安全性和功效非逊皮油支架。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号